Publikationen
2021
Zahradnik J, Marciano S, Shemesh M, Zoler E, Chiaravalli J, Meyer B et al.
SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor.
biorxiv, doi: https://doi.org/10.1101/2021.01.06.425392
Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K et al.
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
Science 2021 Aug 20;373(6557):931-936. doi: 10.1126/science.abg5827. Epub 2021 Jul 20.
Meyer B, Chiaravalli J, Gellenoncourt S, Brownridge P, Bryne DP, Daly LA et al.
Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing.
BioRxiv, 2020.09. 16.297945, doi: https://doi.org/10.1101/2020.09.16.297945
Rezelj VV, Carrau L, Merwaiss F, Levi LI, Erazo D, Tran QD et al.
Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts.
Meyer B, Chiaravalli J, Gellenoncourt S, Brownridge P, Bryne DP, Daly LA et al.
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.
Nat Commun 12 (5553) doi: 10.1038/s41467-021-25796-w.
Lavigne M, Helynck O, Rigolet P, Chiavarelli J, Meyer B, Nowakowski M et al.
The SARS-CoV-2 Nsp3 Unique Domain (SUD) interacts with Guanine quadruplexes and this interaction is a potential antiviral target.
Virologie ; 25(SUPPL 1):S36, 2021.
2020
Bouhaddou M*, Memon D*, Meyer B*, White KM*, Rezelj VV* et al.
The global phosphorylation landscape of SARS-CoV-2 infection.
Cell. 2020 Aug 6;182(3):685-712.e19. doi: 10.1016/j.cell.2020.06.034. Epub 2020 Jun 28.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM et al.
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’meara MJ et al.
A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing.
bioRxiv. Preprint posted March 22, https://doi.org/10.1101/2020.03.22.002386
RNA-seq accuracy and reproducibility for the mapping and quantification of influenza defective viral genomes.
2018
Meyer B, Groseth A.
Apoptosis during arenavirus infection: mechanisms and evasion strategies.
Microbes Infect. 2018 Feb;20(2):65-80. doi: 10.1016/j.micinf.2017.10.002.
2016
Meyer B, Ly H.
Inhibition of innate immune responses is key to pathogenesis by arenaviruses.
J Virol. 2016 Mar 28;90(8):3810-3818. doi: 10.1128/JVI.03049-15. Print 2016 Apr.
The New World Arenavirus Tacaribe induces caspase-dependent apoptosis in infected cells.
J Gen Virol. 2016 Apr;97(4):855-866. doi: 10.1099/jgv.0.000403. Epub 2016 Jan 14.
2015
Meyer B, Ly H.
Immunosupressive arenaviral exoribonuclease.
Oncotarget 6 (32), 32315-32316. doi: 10.18632/oncotarget.6110.
Meyer B, Dupex WP.
Communicate, Educate – Tackling misconceptions to boost vaccine-uptake.
Fut Virol. 10 (9), 1029-1032. DOI:10.2217/FVL.15.74, Corpus ID: 72967909
2014
Meyer B.
Molecular studies of the Tacaribe virus nucleoprotein (NP): identification and characterisation of virus-host interactions as novel anti-arenavirus drug targets.
University of St. Andrews
2012
McRobbie AM, Meyer B, Rouillon C, Petrovic-Stojanovska B, Liu H et al.
Staphylococcus aureus DinG, a helicase that has evolved into a nuclease.
Biochem J. 2012 Feb 15;442(1):77-84. doi: 10.1042/BJ20111903.